LOGIN  |  REGISTER
Viking Therapeutics
Chimerix

Nutex Health Reports Third Quarter 2023 Financial Results

November 09, 2023 | Last Trade: US$30.28 1.49 -4.69
  • NET REVENUE OF $62.7 MILLION
  • NET CASH FROM OPERATING ACTIVITIES OF $2.0 MILLION
  • COMPANY EXPECTS TO OPEN FIVE NEW MICRO-HOPITALS IN 2024

HOUSTON, Nov. 9, 2023 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ: NUTX), a physician-led, technology-enabled integrated healthcare delivery system comprised of 22 state-of-the-art micro-hospitals in 8 states and primary care-centric, risk-bearing physician networks, today announced third quarter 2023 financial results for the three months and nine months ended September 30, 2023.

Financial Highlights for the Three Months and Nine Months Ended September 30, 2023:

  • Net revenue of $62.7 million in Q3 2023 vs $28.4 million in Q3 2022.
  • Net revenue of $178.0 million for the first nine months of 2023 vs $165.6 million for the first nine months of 2022.
  • Gross profit of $7.0 million in Q3 2023 vs net loss of $(23.7) million in Q3 2022.
  • Gross profit of $21.6 million for the first nine months of 2023 vs $18.7 million for the first nine months of 2022.
  • Adjusted EBITDA of $1.3 million in Q3 2023.
  • Adjusted EBITDA of $7.7 million for the first nine months of 2023.
  • Nutex Health does not add back non-recurring costs related to the opening of its new micro-hospitals in its Adjusted EBITDA numbers. Please see our reconciliation of non-GAAP to GAAP measures below.
  • Net cash from operating activities of $2.0 million in Q3 2023 and $3.0 million for the first nine months of 2023.
  • Net loss attributable to Nutex Health of $(5.5) million in Q3 2023 and $(14.2) million for the first nine months of 2023.
  • As of September 30, 2023, the Company had total assets of $479.6 million, including cash and cash equivalents of $26.8 million.

Note:  Adjusted EBITDA is a non-GAAP financial metric.  A reconciliation of non-GAAP to GAAP measures is included below in this earnings release.

Q3 2023 Highlights:

  • On July 5, 2023, Nutex Health opened its third new micro-hospital in 2023 in Louisiana. The facility is performing above expectations.
  • On August 7, 2023, Nutex Health opened its fourth new micro-hospital in 2023 in Royce City, Texas. The facility is performing above expectations. 
  • Nutex Health expects to open five new micro-hospitals in 2024.
  • On August 21, 2023, Nutex Health announced the acquisition of two independent practice associations ("IPAs") in South Florida: Population Health Associates, Inc. ("PHA") and Managed Care Insurance Consultants ("MCIC"). The two IPAs provide high-quality, coordinated care to over 4,400 managed care patients through a network of over 112 primary care physicians in South, Central and North Florida.
  • Additionally, Nutex Health launched three new independent practice associations ("IPAs") in 2023. Our IPAs in South Florida and Houston are actively enrolling patients during the 2023 Medicare Annual Enrollment Period ("AEP"). 
  • On September 5, 2023, Nutex Health announced the appointment of Josh DeTillio as the Company's Chief Operating Officer.  Mr. DeTillio is an experienced healthcare leader with over 20 years of hospital experience and 12 years as a CEO in publicly traded companies.
  • In September 2023, the Company commenced a private offering (the "September 2023 Private Offering") of up to $15.0 million pursuant to which the Company will issue investment units (the "Units") at $50,000 per Unit to accredited investors (the "Unit Holder") as defined in Rule 501 under the 1933 Act. Unit consists of (a) an interest-bearing unsecured convertible promissory note (the "Unsecured Convertible Term Notes") in the principal amount of $50,000 convertible into shares of common stock at a conversion price of $0.40 per share and (b) a six-year warrant (the "Warrants") to purchase up to 62,500 shares of common stock at an exercise price of $0.40 per share. The Notes mature on October 31, 2025 and the Warrants expire on December 31, 2029. As of September 30, 2023, the Company received net cash proceeds of $0.9 million.  As of November 6, 2023, the Company has received net cash proceeds of $4.4 million.
  • The Company has a committed investment agreement for up to $100 million with Lincoln Park Capital, none of which has been used.

NSA Update:

  • On August 24, 2023 the U.S. District Court in the Eastern District of Texas in TMA III ruled to vacate several aspects of the regulations mandating the methodology for the QPA calculation. In particular, the court prohibited the inclusion of "ghost rates" as part of the QPA calculation and QPA calculations that are not based on the same or similar specialty. This is the 4th time the federal court has ruled in favor of the Texas Medical Association effective nationwide. In its FAQs dated October 6, 2023, the Department of Labor states that the Department of Justice intends to appeal the court's ruling.
  • On October 6, 2023, CMS announced new guidance in response to the August 2023 ruling in TMA III vacating several provisions of the existing NSA regulations. In the announcement, the Departments state that while they disagree with the court's ruling, the QPA calculations must now be made in good faith in accordance with the NSA and applicable rules currently in effect, with no additional guidance provided by the Departments and a suspension of any enforcement until at least May 1, 2024, to give the insurers adequate time to comply with the TMA III court ruling. Our management team is actively working with legislatures, the Administration, and the Center for Consumer Information and Insurance Oversight (CCIIO) to request CMS to promptly issue specific guidance on health plan obligations to calculate QPAs in line with the federal district court ruling and issue additional instructions to certified IDR entities on how to evaluate QPAs that are based on an invalidated methodology.
  • On October 27, 2023, the Departments of HHS, Labor, and the Treasury, along with the Office of Personnel Management, released a proposed rule on the NSA's Federal IDR process. The proposed rules would allow: better communication between health plans and providers, open negotiations through a centralized Federal IDR portal, improved IDR eligibility determinations and batching ability of claims.  We do not know when and in what form these proposed rules will be implemented, however, we feel that this is a favorable step in the right direction to repair the faulty implementation of the NSA.

"Our balance sheet continues to remain strong with $26.8 million of cash on hand and significant capital available to handle the development of the five additional micro-hospitals we plan to open in 2024, in addition to forming new IPAs and growing our existing IPAs," stated Jon Bates, Chief Financial Officer of Nutex Health. 

"We are executing on our goal of opening new hospitals and growing volumes and service lines at our existing hospitals. In addition, we are actively enrolling patients in our South Florida and Houston IPAs during the 2023 Medicare Annual Enrollment Period and executing on our integrated healthcare delivery model comprised of micro-hospitals surrounded by risk-bearing physician networks. We believe that this is a novel and innovative model that we can replicate across the country. On the NSA side, we are actively working with legislators and members of CCIIO, as well as the Biden-Harris Administration to correct the flawed implementation of the NSA," stated Tom Vo, M.D., MBA, Chairman and Chief Executive Officer of Nutex Health. 

"In the first nine months of 2023, we have delivered three successive quarters with positive net cash from operating activities and positive adjusted EBITDA while opening four new micro-hospitals, one new urgent care center and launching three new IPAs. We intend to continue to execute on our growth strategy and are confident in our outlook for 2024.  On the capital markets side, with cash on hand and proceeds from our private offering, we intend to pay off the remaining $5.6 million outstanding of our pre-paid advance from Yorkville Advisors prior to the end of the year, with the goal of mitigating the selling pressure on our stock. We expect our board to base its decision regarding the reverse stock split on our trading price and an extension of our existing grace period," stated Warren Hosseinion, M.D., President of Nutex Health. 

For more details on the Company's Third Quarter 2023 financial results, please refer to our Quarterly Report on Form 10-Q filed with the U.S. Securities & Exchange Commission and accessible at www.sec.gov.

NUTEX HEALTH INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(UNAUDITED)

       
  

September 30, 2023

 

December 31, 2022

Assets

      

Current assets:

      

Cash and cash equivalents

 

$

26,826,733

 

$

34,255,264

Accounts receivable

  

53,209,834

  

57,777,386

Accounts receivable - related parties

  

1,487,591

  

538,183

Inventories

  

2,682,716

  

3,533,285

Prepaid expenses and other current assets

  

5,645,296

  

1,869,806

Total current assets

  

89,852,170

  

97,973,924

Property and equipment, net

  

85,496,612

  

82,094,352

Operating right-of-use assets

  

16,712,230

  

20,466,632

Finance right-of-use assets

  

247,593,480

  

192,591,624

Intangible assets, net

  

21,624,132

  

21,191,390

Goodwill, net

  

17,935,036

  

17,010,637

Other assets

  

419,882

  

423,426

       

Total assets

 

$

479,633,542

 

$

431,751,985

       

Liabilities and Equity

      

Current liabilities:

      

Accounts payable

 

$

17,599,047

 

$

23,614,387

Accounts payable - related parties

  

6,144,188

  

3,915,661

Lines of credit

  

3,371,676

  

2,623,479

Current portion of long-term debt

  

19,644,656

  

12,546,097

Operating lease liabilities, current portion

  

1,562,385

  

1,703,014

Finance lease liabilities, current portion

  

4,171,489

  

4,219,518

Accrued expenses and other current liabilities

  

14,773,273

  

6,240,813

Total current liabilities

  

67,266,714

  

54,862,969

Long-term debt, net

  

19,303,829

  

23,051,152

Operating lease liabilities, net

  

15,874,261

  

19,438,497

Finance lease liabilities, net

  

263,791,711

  

203,619,756

Deferred tax liabilities

  

8,492,294

  

10,452,211

Total liabilities

  

374,728,809

  

311,424,585

       

Commitments and contingencies

      
       

Equity:

      

Common stock, $0.001 par value; 950,000,000 shares authorized; 670,711,741 and 650,223,840

shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively

  

670,712

  

650,224

Additional paid-in capital

  

466,711,720

  

458,498,402

Accumulated deficit

  

(377,454,642)

  

(363,285,925)

Nutex Health Inc. equity

  

89,927,790

  

95,862,701

Noncontrolling interests

  

14,976,943

  

24,464,699

Total equity

  

104,904,733

  

120,327,400

       

Total liabilities and equity

 

$

479,633,542

 

$

431,751,985

 

NUTEX HEALTH INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)

             
  

Three Months Ended September 30, 

 

Nine Months Ended September 30, 

  

2023

 

2022

 

2023

 

2022

Revenue:

            

Hospital division

 

$

54,585,263

 

$

21,244,305

 

$

155,485,230

 

$

151,976,226

Population health management division

  

8,137,709

  

7,150,753

  

22,491,613

  

13,594,007

Total revenue

  

62,722,972

  

28,395,058

  

177,976,843

  

165,570,233

             

Operating costs and expenses:

            

Payroll and benefits

  

28,873,144

  

29,048,207

  

79,570,519

  

79,014,608

Contract services

  

9,035,650

  

8,557,373

  

27,972,854

  

26,536,452

Medical supplies

  

3,460,130

  

2,486,083

  

10,748,214

  

9,327,114

Depreciation and amortization

  

4,745,941

  

4,330,167

  

12,908,848

  

9,859,513

Other

  

9,541,894

  

7,686,132

  

25,215,549

  

22,092,033

Total operating costs and expenses

  

55,656,759

  

52,107,962

  

156,415,984

  

146,829,720

             

Gross profit (loss)

  

7,066,213

  

(23,712,904)

  

21,560,859

  

18,740,513

             

Corporate and other costs:

            

Facilities closing costs

  

-

  

-

  

217,266

  

-

Acquisition costs

  

43,464

  

-

  

43,464

  

3,885,666

Stock-based compensation expense

  

49,167

  

81,249

  

2,198,812

  

135,415

Impairment of goodwill

  

-

  

398,135,038

  

-

  

398,135,038

General and administrative expenses

  

7,794,808

  

6,751,548

  

24,730,168

  

17,404,637

Total corporate and other costs

  

7,887,439

  

404,967,835

  

27,189,710

  

419,560,756

             

Operating loss

  

(821,226)

  

(428,680,739)

  

(5,628,851)

  

(400,820,243)

             

Interest expense, net

  

4,098,179

  

3,402,606

  

12,081,316

  

9,628,189

Other expense (income)

  

(53,206)

  

(630,450)

  

70,721

  

346,873

Loss before taxes

  

(4,866,199)

  

(431,452,895)

  

(17,780,888)

  

(410,795,305)

             

Income tax expense (benefit)

  

(342,259)

  

(8,543,880)

  

(2,068,530)

  

11,285,729

             

Net loss

  

(4,523,940)

  

(422,909,015)

  

(15,712,358)

  

(422,081,034)

             

Less: net income (loss) attributable to noncontrolling interests

  

1,018,451

  

(10,722,749)

  

(1,543,641)

  

(12,052,765)

             

Net loss attributable to Nutex Health Inc.

 

$

(5,542,391)

 

$

(412,186,266)

 

$

(14,168,717)

 

$

(410,028,269)

             

Loss per common share:

            

Basic

 

$

(0.01)

 

$

(0.62)

 

$

(0.02)

 

$

(0.65)

Diluted

 

$

(0.01)

 

$

(0.62)

 

$

(0.02)

 

$

(0.65)

 

NUTEX HEALTH INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

       
  

Nine Months Ended September 30, 

  

2023

 

2022

Cash flows from operating activities:

      

Net loss

 

$

(15,712,358)

 

$

(422,081,034)

Adjustments to reconcile net loss to net cash from operating activities:

      

Depreciation and amortization

  

12,908,848

  

9,859,513

Impairment of goodwill

  

-

  

398,135,038

Stock-based compensation expense

  

2,198,812

  

135,415

Deferred tax expense (benefit)

  

(2,068,530)

  

3,375,106

Debt accretion expense

  

1,251,867

  

1,719,572

Loss on lease termination

  

58,210

  

-

Non-cash lease expense

  

89,338

  

18,775

Changes in operating assets and liabilities, net of the effects of acquisitions:

      

Accounts receivable

  

4,444,706

  

52,921,095

Accounts receivable - related party

  

(949,408)

  

1,846,887

Inventories

  

850,569

  

(399,198)

Prepaid expenses and other current assets

  

(3,771,946)

  

(5,658,746)

Accounts payable

  

(6,015,250)

  

4,147,170

Accounts payable - related party

  

2,228,527

  

(630,490)

Accrued expenses and other current liabilities

  

7,519,285

  

2,712,011

Net cash from operating activities

  

3,032,670

  

46,101,114

       

Cash flows from investing activities:

      

Acquisitions of property and equipment

  

(10,322,487)

  

(22,512,464)

Payments for acquisitions of businesses, net of cash acquired

  

(743,837)

  

-

Acquired cash in reverse acquisition with Clinigence

  

-

  

12,716,228

Cash related to deconsolidation of Real Estate Entities

  

(1,039,157)

  

(2,421,212)

Net cash from investing activities

  

(12,105,481)

  

(12,217,448)

       

Cash flows from financing activities:

      

Proceeds from lines of credit

  

2,340,911

  

2,592,714

Proceeds from notes payable

  

16,952,905

  

10,126,130

Proceeds from convertible debt

  

891,000

  

-

Repayments of lines of credit

  

(1,592,714)

  

(72,055)

Repayments of notes payable

  

(10,557,758)

  

(4,720,737)

Repayments of finance leases

  

(2,704,082)

  

(923,321)

Common stock issued for exercise of warrants

  

-

  

4,119,141

Common stock issued for exercise of options

  

-

  

644,974

Members' contributions

  

649,550

  

4,825,377

Members' distributions

  

(4,335,532)

  

(49,973,374)

Net cash from financing activities

  

1,644,280

  

(33,381,151)

Net change in cash and cash equivalents

  

(7,428,531)

  

502,515

Cash and cash equivalents - beginning of the period

  

34,255,264

  

36,118,284

Cash and cash equivalents - end of the period

 

$

26,826,733

 

$

36,620,799

 

Non-GAAP Financial Measures

Adjusted EBITDA. Adjusted EBITDA is used as a supplemental non-GAAP financial measure by management and external users of our financial statements, such as industry analysts, investors, lenders and rating agencies. We believe Adjusted EBITDA is useful because it allows us to more effectively evaluate our operating performance.

We define Adjusted EBITDA as net income (loss) attributable to Nutex Health Inc. plus net interest expense, income taxes, depreciation and amortization, further adjusted for stock-based compensation, certain defined items of expense, any acquisition-related costs and impairments. A reconciliation of net income to Adjusted EBITDA is included below. Adjusted EBITDA is not intended to serve as an alternative to U.S. GAAP measures of performance and may not be comparable to similarly-titled measures presented by other companies. 

             
  

Three Months Ended September 30, 

 

Nine Months Ended September 30, 

  

2023

 

2022

 

2023

 

2022

Reconciliation of net income (loss) attributable to Nutex Health Inc. to Adjusted EBITDA:

            

Net loss attributable to Nutex Health Inc.

 

$

(5,542,391)

 

$

(412,186,266)

 

$

(14,168,717)

 

$

(410,028,269)

Depreciation and amortization

  

4,745,941

  

4,330,167

  

12,908,848

  

9,859,513

Interest expense, net

  

4,098,179

  

3,402,606

  

12,081,316

  

9,628,189

Income tax expense (benefit)

  

(342,259)

  

(8,543,880)

  

(2,068,530)

  

11,285,729

Allocation to noncontrolling interests

  

(1,772,908)

  

(922,762)

  

(3,500,873)

  

(4,445,224)

EBITDA

  

1,186,562

  

(413,920,135)

  

5,252,044

  

(383,700,062)

Facilities closing costs

  

-

  

-

  

217,266

  

-

Impairment of goodwill

  

-

  

398,135,038

  

-

  

398,135,038

Acquisition costs

  

43,464

  

-

  

43,464

  

3,885,666

Stock-based compensation expense

  

49,167

  

81,249

  

2,198,812

  

135,415

Adjusted EBITDA

 

$

1,279,193

 

$

(15,703,848)

 

$

7,711,586

 

$

18,456,057

About Nutex Health Inc.

Headquartered in Houston, Texas and founded in 2011, Nutex Health Inc. (NASDAQ: NUTX) is a healthcare management and operations company with two divisions: a Hospital Division and a Population Health Management Division.

The Hospital Division owns, develops and operates innovative health care models, including micro-hospitals, specialty hospitals, and hospital outpatient departments (HOPDs). This division owns and operates 22 facilities in 8 states.

The Population Health Management division owns and operates provider networks such as Independent Physician Associations (IPAs). Through our Management Services Organization (MSO), we provide management, administrative and other support services to our affiliated hospitals and physician groups.  Our cloud-based proprietary technology platform aggregates clinical and claims data across multiple settings, information systems and sources to create a holistic view of patients and providers, allowing us to deliver greater quality care more efficiently. 

Forward-Looking Statements

Certain statements and information included in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases "will", "will likely result," "expected to," "expects to," "will continue," "anticipated," "estimate," "projected," "intend," "goal," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company.  Such uncertainties and risks include, but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, including final rules implemented under the No Surprises Act and related regulatory guidance, economic conditions, dependence on management, dilution to stockholders, lack of capital, the effects of rapid growth upon the Company and the ability of management to effectively respond to the growth and demand for products and services of the Company, newly developing technologies, the Company's ability to compete, conflicts of interest in related party transactions, regulatory matters, protection of technology, lack of industry standards, the effects of competition and the ability of the Company to obtain future financing. An extensive list of factors that can affect future results are discussed in the Current Report on Form 10-Q for the period ended September 30, 2023 under the heading "Risk Factors" in Part I, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed within this press release.

Terns Pharmaceuticals

Stock Quote

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB